RT-144
|
An update on clinical trials for the primary prevention of sudden cardiac death
|
|
|
Adam Zivin, Gust H. Bardy.
University of Washington Medical Center, Seattle, USA
|
|
References
|
1.
|
CONNOLLY S:
Results from the Canadian Implantable Defibrillator Study (CIDS).
In: Late breaking clinical trials. ACC 47th Annual Scientific Sessions; 1998.
|
2.
|
SIEBELS J, KUCK KH:
Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg).
Am Heart J 1994; 127: 1139-1144.
|
3.
|
THE ANTIARRHYTHMICS VERSUS IMPLANTABLE DEFIBRILLATORS (AVID) INVESTIGATORS:
A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
N Engl J Med 1997; 337: 1576-1583.
|
4.
|
PRATT C, GREENWAY P, SCHOENFELD M, HIBBEN M, REIFFEL J:
Exploration of the precision of classifying sudden cardiac death. Implications for the interpretation of clinical trials.
Circulation 1996; 93.
|
5.
|
LUU M, STEVENSON W, STEVENSON L, BARON K, WALDEN J:
Diverse mechanisms of unexpected cardiac arrest in advanced heart failure.
Circulation 1989; 80: 1675-1680.
|
6.
|
NIKOLIC G, BISHOP R, SINGH J:
Sudden death recorded during Holter monitoring.
Circulation 1982; 66: 218-225.
|
7.
|
BAYES DE LUNA A, COUMEL P, LECLERCQ J:
Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases.
Am Heart J 1989; 117: 151-159.
|
8.
|
GRUBMAN E, PAVRI B, SHIPMAN T, BRITTON N, KOCOVIC D:
Cardiac death and stored electrograms in patients with third-generation implantable cardioverter-defibrillators.
J Am Coll Cardiol 1998; 32: 1056-1062.
|
9.
|
KANNEL WB, DOYLE JT, MCNAMARA PM, QUICKENTON P, GORDON T:
Precursors of sudden coronary death. Factors related to the incidence of sudden death.
Circulation 1975; 51: 606-613.
|
10.
|
REICHENBACH DD, MOSS NS, MEYER E:
Pathology of the heart in sudden cardiac death.
Am J Cardiol 1977; 39: 865-872.
|
11.
|
THE SOLVD INVESTIGATORS:
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.
N Engl J Med 1992; 327: 685-691.
|
12.
|
SWERDLOW C, WINKLE R, MASON J:
Determinants of survival in patients with ventricular tachyarrhythmias.
N Engl J Med 1983; 308: 1436-1442.
|
13.
|
KJEKSHUS J:
Arrhythmias and mortality in congestive heart failure.
Am J Cardiol 1990; 65: 421-481.
|
14.
|
ADHAR G, LARSON L, BARDY G, GREENE H:
Sustained ventricular arrhythmias: differences between survivors of cardiac arrest and patients with recurrent sustained ventricular tachycardia.
J Am Coll Cardiol 1988; 12: 159-165.
|
15.
|
BIGGER J, FLEISS J, KLEIGER R, MILLER J, ROLNITSKY L, GROUP TMP-IR:
The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction.
Circulation 1984; 69: 250-258.
|
16.
|
BUXTON A, MARCHLINSKI F, WAXMAN H, FLORES B, CASSIDY D, JOSEPHSON M:
Prognostic factors in nonsustained ventricular tachycardia.
Am J Cardiol 1984; 53: 1275-1279.
|
17.
|
MUKHARJI J, RUDE R, POOLE W, ET AL:
Risk factors for sudden death after acute myocardial infarction: two-year follow-up.
Am J Cardiol 1984; 54: 31-36.
|
18.
|
TRAPPE H-J, BRUGADA P, TALAJIC M, ET AL:
Prognosis of patients with ventricular tachycardia and ventricular fibrillation: role of the underlying etiology.
J Am Coll Cardiol 1988; 12: 166-174.
|
19.
|
WEAVER W, COBB L, HALLSTROM A:
Ambulatory arrhythmias in resuscitated victims of cardiac arrest.
Circulation 1982; 66: 212-217.
|
20.
|
SINGH S, FISHER S, CARSON P, FLETCHER R:
Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy.
J Am Coll Cardiol 1998; 32: 942-947.
|
21.
|
DOVAL H, NUL D, GRANCELLI H, PERRONE S, BORTMAN G, CURIEL R:
Randomised trial of low-dose amiodarone in severe congestive heart failure.
Lancet 1994; 344: 493-498.
|
22.
|
CHEEMA A, SHEU K, PARKER M, KADISH A, GOLDBERGER J:
Nonsustained ventricular tachycardia in the setting of acute myocardial infarction: tachycardia characteristics and their prognostic implications.
Circulation 1998; 98: 2030-2036.
|
23.
|
NEWBY K, THOMPSON T, STEBBINS A, TOPOL E, CALIFF R, NATALE A:
Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes.
Circulation 1998; 98: 2567-2573.
|
24.
|
MOSS A, SCHNITZLER R, GREEN R, DECAMILLA J:
Ventricular arrhythmias 3 weeks after acute myocardial infarction.
Ann Int Medicine 1971; 75: 837-841.
|
25.
|
PACKER M:
Lack of relation between ventricular arrhythmias and sudden death in patients with chronic heart failure.
Circulation 1992; 85: I-50-I-56.
|
26.
|
SCHULZE R, STRAUSS H, PITT B:
Sudden death in the year following myocardial infarction. Relation to ventricular premature contractions in the late hospital phase and left ventricular ejection fraction.
Am J Med 1977; 62: 192-198.
|
27.
|
DICARLO L, MORADY F, SAUVE M, ET AL:
Cardiac arrest and sudden death in patients treated with amiodarone for sustained ventricular tachycardia or ventricular fibrillation: risk stratification based on clinical variables.
Am J Cardiol 1985; 55: 372-374.
|
28.
|
DOVAL H, NUL D, GRANCELLI H, ET AL, FOR THE GESICA-GEMA INVESTIGATORS:
Nonsustained ventricular tachycardia in severe heart failure: independent marker of increased mortality due to sudden death.
Circulation 1996; 94: 3198-3203.
|
29.
|
BIGGER JT JR:
Relation between left ventricular dysfunction and ventricular arrhythmias after myocardial infarction.
Am J Cardiol 1986; 57: 8B-14B.
|
30.
|
VOLPI A, CAVALLI A, FRANZOSI MG, ET AL:
One-year prognosis of primary ventricular fibrillation complicating acute myocardial infarction. The GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto miocardico) investigators.
Am J Cardiol 1989; 63: 1174-1178.
|
31.
|
TEO KK, YUSUF S, FURBERG CD:
Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials.
JAMA 1993; 270: 1589-1595.
|
32.
|
BEHAR S, GOLDBOURT U, REICHER-REISS H, KAPLINSKY E:
Prognosis of acute myocardial infarction complicated by primary ventricular fibrillation. Principal Investigators of the SPRINT Study.
Am J Cardiol 1990; 66: 1208-1211.
|
33.
|
GOMES J, HARIMAN R, KANG P, EL-SHERIF N, CHOWDHRY I, LYONS J:
Programmed electrical stimulation in patients with high-grade ventricular ectopy: electrophysiologic findings and prognosis for survival.
Circulation 1984; 70: 43-51.
|
34.
|
POOLE JE, MATHISEN TL, KUDENCHUK PJ, ET AL:
Long-term outcome in patients who survive out of hospital ventricular fibrillation and undergo electrophysiologic studies: evaluation by electrophysiologic subgroups.
J Am Coll Cardiol 1990; 16: 657-665.
|
35.
|
WILBER D, GARAN H, FINKELSTEIN D, ET AL:
Out of hospital cardiac arrest: use of electrophysiologic testing in the prediction of long-term outcome.
N Engl J Med 1988; 318: 19-24.
|
36.
|
DAS SK, MORADY F, DI CARLO L, ET AL:
Prognostic usefulness of programmed ventricular stimulation in idiopathic dilated cardiomyopathy without symptomatic ventricular arrhythmias.
Am J Cardiol 1986; 58: 998-1000.
|
37.
|
POLL D, MARCHLINSKI F, FALCONE R, JOSEPHSON M, SIMSON M:
Abnormal signal-averaged electrocardiograms in patients with nonischemic congestive cardiomyopathy: relationship to sustained ventricular tachyarrhythmias.
Circulation 1985; 72: 1308-1313.
|
38.
|
CAIN M, AMBOS H, WITKOWSKI F, SOBEL B:
Fast-fourier transform analysis of signal-averaged electrocardiograms for identification of patients prone to sustained ventricular tachycardia.
Circulation 1984; 69: 711-720.
|
39.
|
FARRELL T, BASHIR Y, CRIPPS T, ET AL:
Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram.
J Am Coll Cardiol 1991; 18: 687-697.
|
40.
|
VALKAMA J, HUIKURI H, KOISTINEN J, YLI-MAYRY S, AIRAKSINEN K, MYERBURG R:
Relation between heart rate variability and spontaneous and induced ventricular arrhythmias in pathents with coronary artery disease.
J Am Coll Cardiol 1995; 25: 437-443.
|
41.
|
ROSENBAUM D, JACKSON L, SMITH J, GARAN H, RUSKIN J, COHEN R:
Electrical alternans and vulnerability to ventricular arrhythmias.
N Engl J Med 1994; 330: 235-241.
|
42.
|
ARMOUNDAS AA, OSAKA M, MELA T, ET AL:
T-wave alternans and dispersion of the QT interval as risk stratification markers in patients susceptible to sustained ventricular arrhythmias.
Am J Cardiol 1998; 82: 1127-1129.
|
43.
|
GRIMM W, GLAVERIS C, HOFFMANN J, ET AL:
Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: design and first results of the Marburg Cardiomyopathy Study.
Pacing Clin Electrophysiol 1998; 21: 2551-2556.
|
44.
|
SINGH S, FLETCHER R, FISHER S, FOR THE CHF-STAT INVESTIGATORS:
Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia.
N Engl J Med 1995; 333: 77-82.
|
45.
|
BIGGER J, FOR THE CORONARY ARTERY BYPASS GRAFT (CABG) PATCH TRIAL INVESTIGATORS:
Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery.
N Engl J Med 1997; 337: 1569-1575.
|
46.
|
MOSS A, HALL W, CANNOM D, ET AL:
Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia.
N Engl J Med 1996; 335: 1933-1940.
|
47.
|
Buxton A, for the MUSTT Investigators:
Late breaking clinical trials: The Multicenter Unsustained Tachycardia Trial (MUSTT).
In: American College of Cardiology, 48th Annual Scientific Sessions.
New Orleans LA; 1999.
|
48.
|
THE CONSENSUS TRIAL STUDY GROUP:
Effects of enalapril on mortality in severe congestive heart failure; results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).
N Engl J Med 1987; 316: 1429-1435.
|
49.
|
PFEFFER M, BRAUNWALD E, MOYE L, ET AL, ON BEHALF OF THE SAVE INVESTIGATORS:
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction.
N Engl J Med 1992; 327: 669-677.
|
50.
|
AUSTRALIA/NEW ZEALAND HEART FAILURE RESEARCH COLLABORATIVE GROUP:
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease.
Lancet 1997; 349: 375-380.
|
51.
|
PACKER M, BRISTOW M, COHN J, ET AL, FOR THE US CARVEDILOL HEART FAILURE STUDY GROUP:
The effect of carvedilol on morbidity and mortality inpatients with chronic heart failure.
N Engl J Med 1996; 334: 1349-1355.
|
52.
|
WAAGSTEIN F, BRISTOW M, SWEDBERG K, ET AL:
Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group.
Lancet 1993; 342: 1441-1446.
|
53.
|
THE NORWEGIAN MULTICENTER STUDY GROUP:
Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction.
N Engl J Med 1981; 304: 701-807.
|
54.
|
BETA-BLOCKER HEART ATTACK TRIAL RESEARCH GROUP:
A randomized trial of propranolol in patients with acute myo-cardial infarction.
JAMA 1982; 247: 1707-1714.
|
55.
|
GOTTLIEB S, MCCARTER R, VOGEL R:
Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction.
N Engl J Med 1998; 339: 489-497.
|
56.
|
SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP:
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
Lancet 1994; 344: 1383-1389.
|
57.
|
LIPID STUDY GROUP:
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initialcholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.
N Engl J Med 1998; 339: 1349-1357.
|
58.
|
AURICCHIO A, SALO RW:
Acute hemodynamic improvement by pacing in patients with severe congestive heart failure.
Pacing Clin Electrophysiol 1997; 20: 313-324.
|
59.
|
SHINBANE JS, CHU E, DEMARCO T, ET AL:
Evaluation of acute dual-chamber pacing with a range of atrioventricular delays on cardiac performance in refractory heart failure.
J Am Coll Cardiol 1997; 30: 1295-1300.
|
60.
|
GOLD M, FELICIANO Z, GOTTLIEB S, FISHER M:
Dual-chamber pacing with a short atrioventricular delay in congestive heart failure: a randomized study.
J Am Coll Cardiol 1995; 26: 967-973./h3>
|
61.
|
NISHIMURA R, HAYES D, HOLMES D, TAJIK J:
Mechanism of hemodynamic improvement by dual-chamber pacing for severe left ventricular dysfunction: an acute doppler and catheterization hemodynamic study.
J Am Coll Cardiol 1995; 25: 281-288.
|
62.
|
AURICCHIO A, STELLBRINK C, SACK S, ET AL, FOR THE PATH-CHF STUDY GROUP:
The pacing therapies for congestive heart failure (PATH-CHF) study: rationale, design, and endpoints of a prospective randomized multicenter study.
Am J Cardiol 1999; 83: 130D-135D.
|
63.
|
SAXON L, BOEHMER J, HUMMEL J, ET AL, FOR THE VIGOR CHF AND VENTAK CHF INVESTIGATORS:
Biventricular pacing in patients with congestive heart failure: two prospective randomized trials.
Am J Cardiol 1999; 83: 120D-123D.
|
64.
|
CAZEAU S, RITTER P, LAZARUS A, ET AL:
Multisite pacing for end-stage heart failure: early experience.
Pacing Clin Electrophysiol 1996; 19: 1748-1757.
|
65.
|
GRAS D, MABO P, TANG T, ET AL:
Multisite pacing as a supplemental treatment of congestive heart failure: preliminary results of the Medtronic Inc. InSync Study.
Pacing Clin Electrophysiol 1998; 21: 2249-2255.
|
66.
|
ECHT D, LIEBSON P, MITCHELL L, ET AL, THE CAST INVESTIGATORS:
Mortality and morbidity in patients receiving encainide,flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial.
N Engl J Med 1991; 324: 781-788.
|
67.
|
THE CARDIAC ARRHYTHMIA SUPPRESSION TRIAL II INVESTIGATORS:
Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction.
N Engl J Med 1992; 327: 227-233.
|
68.
|
IMPACT RESEARCH GROUP:
International mexilitine and placebo antiarrhythmic coronary trial. Report on arrhythmia and other findings.
J Am Coll Cardiol 1984; 4: 1148-1163.
|
69.
|
KUCK K:
Cardiac Arrest Study Hamburg.
In: Late breaking clinical trials I.
ACC 47th Annual Scientific Sessions; 1998.
|
70.
|
CAMM A, KARAM R, PRATT C:
The azimilide post-infarct survival evaluation (ALIVE) trial.
Am J Cardiol 1998; 81: 35D-39D.
|
71.
|
THE DIAMOND STUDY GROUP:
Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies.
Clin Cardiol 1997; 20: 704-710.
|
72.
|
WALDO A, CAMM A, DE RUYTER H, ET AL:
Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction.
Lancet 1996; 348: 7-12.
|
73.
|
BURKART F, PFISTERER M, KIOWSKI W, ET AL:
Effect of antiarrhythmic therapy on mortality in survivors of myo-cardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS).
J Am Coll Cardiol 1990; 16: 1711-1718.
|
74.
|
CAIRNS J, CONNOLLY S, ROBERTS R, GENT M:
Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Mhyocardial Infarction Arrhythmia Trial Investigators.
Lancet 1997; 349: 1776.
|
75.
|
JANSE M, MALIK M, CAMM A, JULIAN D, FRANGIN G, SCHWARTZ P:
Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone. A substudy of EMIAT (the European Myocardial Infarct Amiodarone Trial).
Eur Heart J 1998; 19: 85-95.
|
76.
|
GRIMM W, MENZ V, HOFFMANN J, ET AL:
Complications of third-generation implantable cardioverter defibrillator therapy.
PACE 1999; 22: 206-211.
|
